NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31
NewcelX Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026
$2.63+0.13 (+5.20%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 1.2
- Dividend yield
- –
Ownership
Who owns NewcelX's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $375.00K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Julien Ruggieri | 988,996 | 21.60% | 13G (passive) | Oct 30, 2025 |
| Michel Revel | 940,787 | 20.20% | 13D (active) | Oct 30, 2025 |
| Ronald Hafner | 557,131 | 13.20% | 13D (active) | May 22, 2025 |
| Clover Wolf Capital - Limited Partnership | 343,120 | 7.50% | 13G (passive) | Oct 30, 2025 |
| Ronen Twito | 272,399 | 6.00% | 13D (active) | Oct 30, 2025 |
| Alpha Capital Anstalt | 246,996 | 9.99% | 13G (passive) | Oct 10, 2024 |
| League Jinn Sarl | 1,316,267 | 25.30% | 13D (active) | Apr 27, 2026 |
| Armistice Capital, LLC | 129,475 | 9.99% | 13G (passive) | Sep 30, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michel Revel | CSO and Director, 10% owner | 957,530 | 19.96% | Apr 29, 2026 |
| Ronen Twito | Chairman and CEO, Director | 272,399 | 5.68% | Mar 18, 2026 |
| Kfir Molakandov | VP of R&D | – | – | Mar 18, 2026 |
| Omri Hagai | Chief Financial Officer | – | – | Mar 18, 2026 |
| Olivier Samuel | Director | 81,818 | 1.71% | Apr 29, 2026 |
| Tamar Galili | Director | – | – | Mar 18, 2026 |
| Alexander Zwyer | Director | – | – | Mar 18, 2026 |
| Eran Israel Iohan | Director | – | – | Mar 18, 2026 |
| Liora Oren | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Olivier Samuel Director | Apr 27, 2026 | Buy | +81,818 | $2.75 | $225.00K | 81,818 |
| Michel Revel CSO and Director, 10% owner | Apr 27, 2026 | Buy | +54,545 | $2.75 | $150.00K | 957,530 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.